Fig. 2From: Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in USa Cost-effectiveness plane for add-on therapies with omalizumab versus tiotropium. b Cost-effectiveness acceptability curve for standard therapy, and add-on therapies with tiotropium and omalizumabBack to article page